Journal of Experimental Orthopaedics (Jul 2024)

Microfragmented abdominal adipose tissue‐derived stem cells from knee osteoarthritis patients aged 29–65 years demonstrate in vitro stemness and low levels of cellular senescence

  • Freja Aabæk Hammer,
  • Per Hölmich,
  • Jan O. Nehlin,
  • Kilian Vomstein,
  • Lars Blønd,
  • Lisbet Rosenkrantz Hölmich,
  • Kristoffer Weisskirchner Barfod,
  • Jasmin Bagge

DOI
https://doi.org/10.1002/jeo2.12056
Journal volume & issue
Vol. 11, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract Purpose To investigate the level of cellular senescence in stem cells derived from microfragmented abdominal adipose tissue harvested from patients with knee osteoarthritis (OA). Methods Stem cells harvested from microfragmented abdominal adipose tissue from 20 patients with knee OA, aged 29–65 years (mean = 49.8, SD = 9.58), were analysed as a function of patient age and compared with control cells exhibiting signs of cellular senescence. Steady‐state mRNA levels of a panel of genes associated with senescence were measured by qPCR. Intracellular senescence‐associated proteins p16 and p21, and senescence‐associated β‐galactosidase activity were measured by flow cytometry. Cellular proliferation was assessed using a 5‐ethynyl‐2′‐deoxyuridine proliferation assay. Stemness was assessed by stem cell surface markers using flow cytometry and the capacity to undergo adipogenic and osteogenic differentiation in vitro. Results No correlation was found between cellular senescence levels of the microfragmented adipose tissue‐derived stem cells and patient age for any of the standard assays used to quantify senescence. The level of cellular senescence was generally low across all senescence‐associated assays compared to the positive senescence control. Stemness was verified for all samples. An increased capacity to undergo adipogenic differentiation was shown with increasing patient age (p = 0.02). No effect of patient age was found for osteogenic differentiation. Conclusions Autologous microfragmented adipose tissue‐derived stem cells may be used in clinical trials of knee OA of patients aged 29–65 years, at least until passage 4, as they show stemness potential and negligible senescence in vitro. Level of Evidence Not applicable.

Keywords